• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

经尿道膀胱肿瘤切除术治疗非肌层浸润性膀胱癌后的再分期：谁、为何、何时以及如何？

Restaging transurethral resection for non-muscle invasive bladder cancer: who, why, when, and how?

机构信息

Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN 37232, USA.

出版信息

Urol Clin North Am. 2013 May;40(2):295-304. doi: 10.1016/j.ucl.2013.01.009. Epub 2013 Feb 16.

DOI:10.1016/j.ucl.2013.01.009
PMID:23540786
Abstract

The rate of clinical understaging in non-muscle invasive bladder cancer (NMIBC) after an initial transurethral resection (TUR) is significant, particularly for high-grade disease, and this has a major impact on prognosis. A repeat TUR, 2 to 6 weeks following the initial resection, is recommended in appropriately selected cases to avoid diagnostic inaccuracy and improve treatment allocation. This article summarizes the rationale and indications for performing a repeat TUR in NMIBC and also provides information regarding patient selection and technique.

摘要

在初始经尿道切除术 (TUR) 后，非肌肉浸润性膀胱癌 (NMIBC) 的临床分期不足率很高，尤其是对于高级别疾病，这对预后有重大影响。建议在适当选择的病例中重复 TUR，即在初始切除后 2 至 6 周进行，以避免诊断不准确并改善治疗分配。本文总结了在 NMIBC 中进行重复 TUR 的原理和适应证，还提供了有关患者选择和技术的信息。

相似文献

1
Restaging transurethral resection for non-muscle invasive bladder cancer: who, why, when, and how?经尿道膀胱肿瘤切除术治疗非肌层浸润性膀胱癌后的再分期：谁、为何、何时以及如何？
Urol Clin North Am. 2013 May;40(2):295-304. doi: 10.1016/j.ucl.2013.01.009. Epub 2013 Feb 16.
2
Timing and outcomes for radical cystectomy in nonmuscle invasive bladder cancer.非肌层浸润性膀胱癌根治性膀胱切除术的时机和结果。
Curr Opin Urol. 2013 Sep;23(5):423-8. doi: 10.1097/MOU.0b013e328363e46f.
3
The value of a second transurethral resection for T1 bladder cancer.T1期膀胱癌二次经尿道切除术的价值
BJU Int. 2006 Jun;97(6):1199-201. doi: 10.1111/j.1464-410X.2006.06144.x. Epub 2006 Mar 23.
4
Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.高危浅表性膀胱肿瘤患者膀胱内卡介苗治疗失败后的膀胱切除术：术前前列腺受累作为一个预后因素。
Eur Urol. 2005 Jul;48(1):53-9; discussion 59. doi: 10.1016/j.eururo.2005.03.021. Epub 2005 Apr 7.
5
Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy.高危浅表性膀胱癌的再次经尿道切除术可改善对卡介苗治疗的初始反应。
J Urol. 2005 Dec;174(6):2134-7. doi: 10.1097/01.ju.0000181799.81119.fc.
6
[Radical cystectomy in patients with non-muscle invasive bladder cancer who fail BCG therapy].卡介苗治疗失败的非肌层浸润性膀胱癌患者的根治性膀胱切除术
Actas Urol Esp. 2010 Jan;34(1):63-70.
7
Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin.女性性别和前列腺尿道原位癌是 T1G3 膀胱癌患者接受卡介苗治疗后复发、进展和疾病特异性死亡率的预后因素。
Eur Urol. 2012 Jul;62(1):118-25. doi: 10.1016/j.eururo.2011.10.029. Epub 2011 Oct 25.
8
Expression of integrin proteins in non-muscle-invasive bladder cancer: significance of intravesical recurrence after transurethral resection.整合素蛋白在非肌肉浸润性膀胱癌中的表达：经尿道切除术后膀胱内复发的意义。
BJU Int. 2011 Jan;107(2):240-6. doi: 10.1111/j.1464-410X.2010.09534.x. Epub 2010 Aug 24.
9
Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy?T1期膀胱癌再次经尿道切除术能否筛选出适合立即行膀胱切除术的患者？
J Urol. 2007 Jan;177(1):75-9; discussion 79. doi: 10.1016/j.juro.2006.08.070.
10
A re-staging transurethral resection predicts early progression of superficial bladder cancer.再次分期经尿道切除术可预测浅表性膀胱癌的早期进展。
BJU Int. 2006 Jun;97(6):1194-8. doi: 10.1111/j.1464-410X.2006.06145.x. Epub 2006 Mar 23.

引用本文的文献

1
Can a second resection be avoided after initial thulium laser endoscopic en bloc resection for non-muscle invasive bladder cancer? A retrospective single-center study of 251 patients.首次钬激光内镜整块切除术治疗非肌层浸润性膀胱癌后能否避免二次切除术？一项回顾性单中心研究 251 例患者。
BMC Urol. 2020 Mar 18;20(1):30. doi: 10.1186/s12894-020-00599-1.
2
Does restaging transurethral resection of bladder tumour influence outcomes in patients treated with BCG immunotherapy? 491 cases in 20 years' experience.膀胱肿瘤经尿道再切除进行分期会影响接受卡介苗免疫治疗患者的预后吗？20年经验中的491例病例。
Wideochir Inne Tech Maloinwazyjne. 2019 Apr;14(2):284-296. doi: 10.5114/wiitm.2018.79993. Epub 2018 Dec 19.
3
Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015.
加拿大膀胱癌医疗质量改善建议：一份由加拿大膀胱癌协会（BCC）、加拿大泌尿外科肿瘤学组（CUOG）和加拿大泌尿外科协会（CUA）于2015年12月审核并认可的共识文件。
Can Urol Assoc J. 2016 Jan-Feb;10(1-2):E46-80. doi: 10.5489/cuaj.3583. Epub 2016 Feb 8.
4
The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette-Guérin.卡介苗治疗的T1期高级别/3级膀胱癌大型多中心队列中再次经尿道切除术对临床结局的影响
BJU Int. 2016 Jul;118(1):44-52. doi: 10.1111/bju.13354. Epub 2015 Nov 6.